|
Neoplasm Metastasis
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
Due to the heterogeneity of breast cancer and possible discordance in HER2 status between primary tumors and distant metastases, assessment of HER2 expression by noninvasive imaging is important.
|
31470531 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
HER2 status differed between the primary tumor and its metastases in 5/38 cases (13.2%).
|
30957723 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
GeneticVariation
|
phenotype |
BEFREE |
We studied demographics, tumour characteristics, median distant disease-free survival (DDFS), using a time-to-event analysis and time to progression (TTP) and overall survival (OS) upon metastasis, using Kaplan-Meier and log-rank statistics to assess differences between ERBB2-mutation statuses.
|
30456437 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Favorable factors included: triple positive breast cancer [positive hormone receptors and positive human epidermal growth factor receptor 2], which is more hormosensitive and chemosensitive; absence of metastasis; correct endometrium preparation; and the patient's optimistic attitude and strict health habits.
|
30637253 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
The impact of following factors on 5-year disease-free survival (DFS) and overall survival (OS) was studied: age, sex, preoperative 7th nerve palsy, skin infiltration, pT, pN, surgical margin, type of parotidectomy and neck dissection, histology (SDC de novo vs. SDC ex pleomorphic adenoma, SDCexPA), intra/periparotid lymph nodes metastases, perineural invasion (PNI), extraparenchymal extension (EPE), and overexpression HER2.
|
31062093 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
GeneticVariation
|
phenotype |
BEFREE |
The authors searched for patients who had breast carcinoma recurrences or metastases diagnosed between 2010 and 2018 by fine-needle aspiration or by the drainage of body cavity fluids with HER2 IHC and/or FISH performed on formalin-fixed CBs.
|
31544361 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
Nectin-4 cell adhesion molecule and ErbB2 tyrosine kinase receptor are upregulated in many cancers, including breast cancer, and promote cancer cell proliferation and metastasis.
|
31831814 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Subgroup analysis showed that HER2-negative patients experienced a longer OS in the subgroup of tumors 2-4 cm in size, no distant metastasis and who had received radiotherapy, but none of subgroup was found a significant difference in DSS between different HER2 status.
|
31564908 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Patients with hormone receptor (HR)-negative human epidermal growth factor receptor 2 (HER2)-positive (4.4% of entire cohort, 52.5% of patients with metastatic disease to any distant site) and HR-positive HER2-positive (2.8% of entire cohort, 40.4% of patients with metastatic disease to any distant site) subtypes had highest incidence proportions.
|
30487134 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
The cellular expression of both markers was correlated with HER2, ER, and PR status as well as tumor grade, Ki-67 scores, invasion, and metastasis.
|
31004251 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
A prior site of disease (including intracranial metastases) was HER2+ for 13% of evaluable patients: 3 of 11 patients with colorectal cancer and no patients with esophageal or pancreatic cancer.
|
30373904 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Notably, the interval between last HER2-targeted treatment and the time of surgical excision of the tumor after neoadjuvant chemotherapy (NACT) or the biopsy of the metachronous metastasis was associated with a significant change in HER2 expression.
|
30806922 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
Multivariate analysis showed that distant metastasis (95% CI: 1.559 to 4.028, p < 0.001), HER2 high expression (95% CI: 1.058 to 2.454, p = 0.026), and p-PLCγ positivity (95% CI: 1.056 to 2.435, p = 0.027) were independent prognostic predictors of OS in EBVnGC patients.
|
31594682 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusion:</b> Our findings confirm the clinical benefits and safety of retreatment therapy with trastuzumab for HER2-positive patients with metastatic cancer of the breast that had progressed during trastuzumab-based treatment regimens.
|
31213894 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
The mechanisms correlating HER2 with metastasis are poorly understood.
|
30409762 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
This is a retrospective study in which FISH analysis of Her-2/Neu was carried out simultaneously on archived material of 50 cases previously diagnosed as invasive duct carcinoma and the corresponding nodal metastases from the Pathology Department, NCI.
|
29750667 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
Altogether, these data indicate that the inhibition of HER2-induced tumorigenesis by miR-489 overexpression was due to altering progenitor cell populations while decreasing tumor growth and metastasis via influencing tumor promoting genes DEK and SHP2.
|
30104710 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
The main baseline criteria were HER2-negative mBC, performance status 0-2 and no prior chemotherapy for metastatic disease.
|
31773439 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Accordingly, EpCAM corresponds to MCF-7, MUC-1 to MDA-MB-231, and HER-2 to SK-BR-3.
|
31015522 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
We will use the Kaplan-Meier method to estimate cumulative incidence of distant metastasis, distant recurrence-free interval and postmetastasis survival by extent of disease at initial diagnosis, site of metastasis and treatment-defined tumour receptor type (hormone receptor-positive, human epidermal growth factor receptor-2-positive, triple negative).
|
30709862 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
The aim of this study was to analyze the association of hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) based breast cancer subtypes in stage IV inflammatory breast cancer (IBC) with preferential site of distant metastases and overall survival (OS).
|
31623649 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
GeneticVariation
|
phenotype |
BEFREE |
As HER2 mutation is rare, the clinical and pathological features of HER2-mutated breast cancers, such as hormonal status, histological grade, and metastasis, remain poorly defined.
|
31351155 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Our report demonstrates the efficacy of afatinib in a heavily pre-treated <i>HER2</i>-amplified endometrial cancer patient with multi-organ metastasis.
|
31308701 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
This retrospective, exploratory study included patients (≥ 18 years old) treated at our center (2005-2009) who had ER+ , HER2-negative invasive breast cancer and synchronous nodal metastases with available tumor blocks from both sites.
|
31302854 |
2019 |
|
Neoplasm Metastasis
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
TBCP-1 tumours maintain a HER2-positive phenotype in vivo and give rise to a high incidence of spontaneous and experimental metastases in the brain and other organs.
|
31409375 |
2019 |